医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Terumo Europe NV Begins Commercial Distribution of BSD Medical Corporation’s MicroThermX® Microwave Ablation System at European Conference on Interventional Oncology

2013年05月16日 PM10:40
このエントリーをはてなブックマークに追加


 

SALT LAKE CITY

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo Corporation, will begin commercial distribution of the MicroThermX® Microwave Ablation System (MicroThermX) on June 19, 2013, at the annual European Conference on Interventional Oncology (ECIO). In preparation for commercial distribution, Terumo has issued a purchase order to BSD for numerous MicroThermX systems and SynchroWave antennas.

MicroThermX will be the centerpiece for Terumo at the ECIO. Terumo and BSD are co-sponsoring an educational symposium and workshops highlighting the MicroThermX. The symposium will feature two presentations focused solely on MicroThermX. “Microwave for lung tumour ablation: potential advantages compared with radiofrequency ablation and clinical settings” will be presented by Professor Philippe Pereira. “Targeted thermal ablation for liver tumour with MicroThermX microwave ablation system” will be presented by Dr. Sohail Contractor. Both Professor Pereira and Dr. Contractor are leading experts in the field of interventional oncology.

“This exciting introduction by Terumo of the MicroThermX at ECIO will leave Terumo in an excellent position to capture market share in the growing interventional oncology market,” said Harold Wolcott, BSD President and CEO. “BSD’s exclusive distribution agreement with Terumo Europe NV for 100 countries represents one of the most significant milestones in our corporate history. The potential market size for thermal ablation in these countries is estimated to be in excess of $1 billion in annual sales.”

About ECIO

ECIO is a comprehensive international meeting focused exclusively on the rapidly growing field of interventional oncology, a key market for BSD’s ablation products. Leading interventional oncology experts from over 60 countries are expected to attend the conference. ECIO will take place from June 19 to 22 in Budapest, Hungary (http://www.ecio.org).

About Terumo Corporation

A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2012 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.

About the MicroThermX® Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX utilizes proprietary synchronous phased array technology that was developed and patented by BSD to provide a wide range of uniform zones of ablation. The MicroThermX includes advanced, high-end disposables (SynchroWave antennas) that are used in each diseased soft tissue (tumor) ablation treatment, which provides a significant ongoing revenue stream. The soft tissue (tumor) ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical’s website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the expected use of proceeds relating to the recently completed offering. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.

CONTACT

BSD Medical Corporation
William Barth, 801-972-5555
fax:
801-972-5930
investor@bsdmc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia